SPRY: neffy share gains and lower spending support a year-end 2027 breakeven target
ARS Pharmaceuticals lifted neffy's U.S. share to 5% in Q3 and cut SG&A, while reaffirming its year-end 2027 cash flow breakeven goal.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
ARS Pharmaceuticals (ticker SPRY) reported third-quarter revenue of $37.7 million, according to TradingView. Its share of the U.S. market for neffy rose to 5%, and reached 9% among targeted accounts. Demand for neffy grew 42% year over year.
SG&A expenses fell by more than 40% compared with the average quarterly level of the first half. The company held $138.4 million in cash and investments. Management reaffirmed its target of reaching cash flow breakeven by year-end 2027. Interim Phase 2b data for ARS-2 are expected in the first quarter of 2027.
why it matters
For investors, two points stand out: sales are growing while cash outflows shrink, and the liquidity cushion gives the company time to reach its goals. The next key event for the stock will be the interim ARS-2 data.
market impact
SPRY shares: lower spending and faster neffy sales support the breakeven outlook
- SPRY shares pressure up — lower spending and faster sales strengthen the breakeven outlook
tags
instruments
sources
- SPRY: neffy share gains and lower SG&A underpin a year-end 2027 breakeven target — TradingView, 5 November 2026 at 21:06 UTC
- SPRY: neffy gained share as spending fell, supporting the year-end 2027 breakeven target — TradingView, 5 November 2026 at 22:41 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗